Vioxx, the implosion of Merck, and aftershocks at the FDA
- 1 December 2004
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 364 (9450) , 1995-1996
- https://doi.org/10.1016/s0140-6736(04)17523-5
Abstract
No abstract availableKeywords
This publication has 2 references indexed in Scilit:
- Failing the Public Health — Rofecoxib, Merck, and the FDANew England Journal of Medicine, 2004
- Vioxx: an unequal partnership between safety and efficacyThe Lancet, 2004